{"id":14540,"date":"2012-12-28T09:42:42","date_gmt":"2012-12-28T09:42:42","guid":{"rendered":"http:\/\/semmelweis-egyetem.hu\/hirek\/?p=14540"},"modified":"2012-12-28T09:42:42","modified_gmt":"2012-12-28T09:42:42","slug":"imi-8th-call-2012","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/hirek\/2012\/12\/28\/imi-8th-call-2012\/","title":{"rendered":"IMI 8th Call 2012"},"content":{"rendered":"<p>Key research:<\/p>\n<p>&#8211;  Infectious diseases (correlated to the area of interest: Disease Drug Efficacy)<br \/>\n&#8211; Pharmacogenetics and Taxonomy of Human Diseases (correlated to the area of interests:  Patient, Diseases, Knowledge)<br \/>\n&#8211; Stem Cells for Drug Development and Toxicity Screening (correlated to the area of interests: tools)<\/p>\n<p>Who can apply:<br \/>\n&#8211;\tlarge biopharmaceutical companies that are members of EFPIA,<br \/>\n&#8211;\tand a variety of other partners, such as:<br \/>\n&#8211;\tsmall- and medium-sized enterprises,<br \/>\n&#8211;\tpatients&#8217; organisations,<br \/>\n&#8211;\tuniversities and other research organisations,<br \/>\n&#8211;\thospitals,<br \/>\n&#8211;\tregulatory agencies,<br \/>\n&#8211;\tany other industrial partners.<br \/>\nThe IMI  financial contribution:<\/p>\n<p>&#8211; For research and technological development activities, up to 75% of the eligible costs and<br \/>\n&#8211; For other  activities (including management and training activities) up to 100%<\/p>\n<p>Budget: maximum EUR 143 300 000.<\/p>\n<p>Submissions deadline: 19 March 2013 \u2013 13:00:00 hours Brussels time (CET)<\/p>\n<p>More information: http:\/\/www.imi.europa.eu\/sites\/default\/files\/uploads\/documents\/8th_Call\/IMI_8thCallText_FINAL.pdf<\/p>\n<p>Tov\u00e1bbi inform\u00e1ci\u00f3:\tDr. P\u00f6rzse G\u00e1bor<br \/>\n\tigazgat\u00f3<br \/>\n\tSemmelweis P\u00e1ly\u00e1zati \u00e9s<br \/>\n\tInnov\u00e1ci\u00f3s K\u00f6zpont Kft.<br \/>\n\t1094 Budapest, Ferenc t\u00e9r 15.<br \/>\n\tTel.: 459-1500\/53820<br \/>\n\tFax: 459-1589<br \/>\n\tE-mail: innov@palyazat-sote.hu<br \/>\n\tWeb: www.palyazat-sote.hu<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key research: &#8211; Infectious diseases (correlated to the area of interest: Disease Drug Efficacy) &#8211; Pharmacogenetics and Taxonomy of Human Diseases (correlated to the area of interests: Patient, Diseases, Knowledge) &#8211; Stem Cells for Drug Development and Toxicity Screening (correlated to the area of interests: tools) Who can apply: &#8211; large biopharmaceutical companies that are &hellip;<\/p>\n","protected":false},"author":10,"featured_media":9885,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[150],"tags":[],"class_list":["post-14540","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-palyazatok"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/posts\/14540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/comments?post=14540"}],"version-history":[{"count":0,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/posts\/14540\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/media\/9885"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/media?parent=14540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/categories?post=14540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/hirek\/wp-json\/wp\/v2\/tags?post=14540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}